Cebix

spacer_gradation2.jpg

Recent News

November 18, 2011 Webcast: From the C-peptide symposium in Lisbon, Portugal September 12, 2011 more>>

September 07, 2011 Cebix to Chair Symposium on C-Peptide and the Pathophysiology of Diabetes at European Association for the Study of Diabetes Annual Meeting 2011 more>>

Blog

February 04, 2011 National Diabetes Fact Sheet 2011- CDC more>>

September 28, 2010 Presented by James Callaway, Chief Operating Officer and President of Research and Development Cebix Inc. more>>

Complications of Type 1 Diabetes

retinopathy_complications_headers.jpg

Diabetic retinopathy is an important cause of visual impairment in patients with type 1 diabetes.  It affects primarily the blood vessels of the retina.  Early changes include increased vascular permeability, thickening of the basement membrane of the endothelial cells of the vascular wall, and development of microaneurysms.  These changes eventually lead to formation of retinal edema and exudates, initially with mild visual impairment.  At a later stage, termed proliferative retinopathy, there may be formation of new blood vessels in the retina, growth of fibrous tissue, and hemorrhage of the retina and the vitreous body, leading to severe loss of vision.  At this stage distortion or detachment of the retina may occur, causing further deterioration of vision.  Microaneurysms are seen in approximately 80% of type 1 diabetes patients after 10-20 years and proliferative retinopathy may be present in 40-50% after 20 years.  Intensive insulin treatment and optimal blood glucose control slows or halts the progression of retinal changes.  Advanced changes may be treated by laser photocoagulation, but no causal treatment is available.

{embed="redesign_inc/html_footer"